Review

Pre-existing immunity against vaccine vectors – friend or foe?

  • 1Ludwig Institute for Cancer Research, Heidelberg, Victoria, Australia
  • 2School of Applied Sciences, RMIT University, Bundoora, Victoria, Australia
  • 3Comparative Genomics Centre, School of Pharmacy and Molecular Sciences, James Cook University, Townsville, Queensland, Australia
  • Correspondence
    Peter M. Smooker peter.smooker{at}rmit.edu.au
  • Microbiology 2013; 159(Pt 1):1–11 · https://doi.org/10.1099/mic.0.049601-0

    View at publisher PubMed

    Abstract

    Over the last century, the successful attenuation of multiple bacterial and viral pathogens has led to an effective, robust and safe form of vaccination. Recently, these vaccines have been evaluated as delivery vectors for heterologous antigens, as a means of simultaneous vaccination against two pathogens. The general consensus from published studies is that these vaccine vectors have the potential to be both safe and efficacious. However, some of the commonly employed vectors, for example Salmonella and adenovirus, often have pre-existing immune responses in the host and this has the potential to modify the subsequent immune response to a vectored antigen. This review examines the literature on this topic, and concludes that for bacterial vectors there can in fact, in some cases, be an enhancement in immunogenicity, typically humoral, while for viral vectors pre-existing immunity is a hindrance for subsequent induction of cell-mediated responses.

    • These authors contributed equally to this work.

    This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.